文献速递瓣膜外科

三尖瓣感染性心内膜炎的外科治疗:系统综述与荟萃分析

Surgical Management of Tricuspid Valve Infective Endocarditis: A Systematic Review and Meta-Analysis.
PubMed 文献 · Ann Thorac Surg · 2018-05-08

该系统综述与荟萃分析比较三尖瓣感染性心内膜炎瓣膜修复与置换的早期和晚期结局,纳入12项非匹配回顾性观察研究共1165例患者(中位随访3.8年)。结果显示两组围术期死亡和长期全因死亡无差异,修复与较低复发感染和再手术需求相关,但中重度三尖瓣反流风险有升高趋势。

要点

  • 三尖瓣修复与置换的围术期死亡(RR 0.62,95%CI 0.26-1.46)和长期全因死亡(RR 0.61,95%CI 0.22-1.72)无显著差异。
  • 修复与较低复发感染(RR 0.17,95%CI 0.05-0.57)和再手术需求(RR 0.26,95%CI 0.07-0.92)相关。
  • 修复与较低永久起搏器需求相关(RR 0.20,95%CI 0.11-0.35),但中重度三尖瓣反流风险有升高趋势(RR 4.14,95%CI 0.80-21.34)。

核心结论

  • 三尖瓣修复与置换提供相似的长期生存。
  • 瓣膜修复可能提供更高的免受复发感染和再手术以及免受起搏器植入的自由度,应作为三尖瓣感染性心内膜炎患者的首选方法。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE和EMBASE数据库至2016年,纳入比较三尖瓣修复与置换的研究。
  • 纳入12项非匹配回顾性观察研究,共1165例患者,中位随访3.8年(四分位距2.1至5.0年)。

主要发现

  • 研究中最常见的手术指征为脓毒性肺栓塞、左侧感染性心内膜炎、右心衰竭和持续性菌血症。
  • 研究中修复比例中位数为59%,置换比例中位数为41%。
  • 主要修复策略为赘生物切除、De Vega成形、瓣环成形环、二瓣化及瓣叶补片扩大。
  • 瓣膜置换中83%为生物瓣,17%为机械瓣。
  • 围术期死亡两组无差异(RR 0.62,95%CI 0.26-1.46,p=0.3),长期全因死亡无差异(RR 0.61,95%CI 0.22-1.72,p=0.4)。

关键数值与推荐

  • 三尖瓣修复与置换围术期死亡RR 0.62(95%CI 0.26-1.46,p=0.3)。
  • 长期全因死亡RR 0.61(95%CI 0.22-1.72,p=0.4)。
  • 复发感染RR 0.17(95%CI 0.05-0.57,p=0.004)。
  • 再手术需求RR 0.26(95%CI 0.07-0.92,p=0.04)。
  • 中重度三尖瓣反流RR 4.14(95%CI 0.80-21.34,p=0.09);永久起搏器需求RR 0.20(95%CI 0.11-0.35,p<0.001)。

临床怎么用

  • 作者认为瓣膜修复应作为三尖瓣感染性心内膜炎患者的首选方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This meta-analysis compares the early and late outcomes of valve repair versus replacement, the primary surgical strategies for tricuspid valve infective endocarditis (IE). METHODS: We searched MEDLINE and EMBASE databases until 2016 for studies comparing tricuspid valve repair and replacement. RESULTS: The main outcomes were mortality, recurrent IE, and need for reoperation. There were 12 unmatched retrospective observational studies with 1,165 patients (median follow-up 3.8 years, interquartile range: 2.1 to 5.0). The most common indications for surgery were septic pulmonary embolism, left-sided IE, right-side heart failure, and persistent bacteremia. Median repair proportion was 59% and replacement was 41% among studies. The primary repair strategies are vegetectomy, De Vega procedure, annuloplasty ring, bicuspidization, and leaflet patch augmentation. Of valve replacements, 83% were bioprosthetic and 17% mechanical prostheses. There were no differences in perioperative mortality between tricuspid valve repair versus replacement (relative risk [RR] 0.62, 95% confidence interval [CI]: 0.26 to 1.46, p = 0.3). Long-term all-cause mortality was not different (RR 0.61, 95% CI: 0.22 to 1.72, p = 0.4). Valve repair was associated with lower recurrent IE (RR 0.17, 95% CI: 0.05 to 0.57, p = 0.004) and need for reoperation (RR 0.26, 95% CI: 0.07 to 0.92, p = 0.04) but a trend toward greater risk of moderate to severe tricuspid regurgitation (RR 4.14, 95% CI: 0.80 to 21.34, p = 0.09). Furthermore, tricuspid valve repair is associated with lower need for permanent pacemaker (RR 0.20, 95% CI: 0.11 to 0.35, p < 0.001). CONCLUSIONS: Tricuspid valve repair and replacement offer similar long-term survival. Valve repair may offer greater freedom from recurrent IE and reoperation as well as freedom from pacemaker and should be the preferred approach for patients with tricuspid valve IE.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Yanagawa B, Elbatarny M, Verma S, et al. Surgical Management of Tricuspid Valve Infective Endocarditis: A Systematic Review and Meta-Analysis. Ann Thorac Surg. 2018. PMID: 29750928. doi:10.1016/j.athoracsur.2018.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。